Allena Pharmaceuticals, Inc.
|Number of Estimates|
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.
Market Cap: 49.4 Million
Primary Exchange: NASDAQ
Shares Outstanding: 32.1 Million
Float: 21.6 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 584 trading days
From: 2018-04-04 To: 2020-07-02
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|